How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

129,191 results for

Demulen 1/35

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β. (PubMed)

A Luciferase Reporter Gene Assay to Measure Ebola Virus Viral Protein 35-Associated Inhibition of Double-Stranded RNA-Stimulated, Retinoic Acid-Inducible Gene 1-Mediated Induction of Interferon β. During Ebola virus (EBOV) infection, the type I interferon α/β (IFN-α/β) innate immune response is suppressed by EBOV viral protein 35 (VP35), a validated drug target. Identification of EBOV VP35 inhibitors requires a cellular system able to assess the VP35-based inhibitory functions of viral double

Full Text available with Trip Pro

2015 Journal of Infectious Diseases

162. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. (PubMed)

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues, but there are few data on the safety (...) and immunogenicity of rAd35 directly compared to rAd5 following human vaccination.HVTN 077 randomized 192 healthy, HIV-uninfected participants into one of four HIV-1 vaccine/placebo groups: rAd35/rAd5, DNA/rAd5, and DNA/rAd35 in Ad5-seronegative persons; and DNA/rAd35 in Ad5-seropositive persons. All vaccines encoded the HIV-1 EnvA antigen. Antibody and T-cell responses were measured 4 weeks post boost immunization.All vaccines were generally well tolerated and similarly immunogenic. As compared to rAd5, rAd35

Full Text available with Trip Pro

2015 Journal of AIDS & clinical research Controlled trial quality: uncertain

163. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. (PubMed)

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. Sequential prime-boost or co-administration of HIV vaccine candidates based on an adjuvanted clade B p24, RT, Nef, p17 fusion protein (F4/AS01) plus a non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN) may lead to a unique immune profile (...) , inducing both strong T-cell and antibody responses.In a phase 1, double-blind, placebo-controlled trial, 146 healthy adult volunteers were randomized to one of four regimens: heterologous prime-boost with two doses of F4/AS01E or F4/AS01B followed by Ad35-GRIN; Ad35-GRIN followed by two doses of F4/AS01B; or three co-administrations of Ad35-GRIN and F4/AS01B. T cell and antibody responses were measured.The vaccines were generally well-tolerated, and did not cause serious adverse events. The response

Full Text available with Trip Pro

2015 PloS one Controlled trial quality: uncertain

164. The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. (PubMed)

The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and daily 5-mg risedronate dosing regimens in the treatment of Chinese postmenopausal women with osteoporosis or osteopenia.Postmenopausal (...) women with primary osteoporosis or osteopenia were randomly assigned to the weekly group or daily group (n=145 for each) that received oral risedronate 35 mg once a week or 5 mg daily, respectively, for 1 year. The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments.All subjects in the weekly group and 144 subjects in the daily group completed the study. The primary efficacy

Full Text available with Trip Pro

2015 Acta pharmacologica Sinica Controlled trial quality: predicted high

165. Di­chlorido­[6,8,22,24,34,36-hexa­methyl-33,35-diaza-3,11,19,27-tetra­azonia­penta­cyclo[27.3.1.15,9.113,17.121,25]hexa­triaconta-1(33),5,7,9(34),13,15,17(35),21,23,25(36),29,31-dodeca­ene-κ6 N 3,N 11,N 19,N 27,N 33,N 35]dipalladium(II) bis(per­ (PubMed)

Di­chlorido­[6,8,22,24,34,36-hexa­methyl-33,35-diaza-3,11,19,27-tetra­azonia­penta­cyclo[27.3.1.15,9.113,17.121,25]hexa­triaconta-1(33),5,7,9(34),13,15,17(35),21,23,25(36),29,31-dodeca­ene-κ6 N 3,N 11,N 19,N 27,N 33,N 35]dipalladium(II) bis(per­ In the crystal structure of the title compound, [Pd2(C36H42N6)Cl2](ClO4)2·2C3H7NO·2CH3OH, the dinuclear Pd(II) complex cation lies on an inversion center. Each Pd(II) ion has a distorted square-planar coordination sphere, defined by three N

Full Text available with Trip Pro

2013 Acta Crystallographica Section E: Structure Reports Online

166. Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults?

/kg 7 3,607 4,411 8,676 11,251 Serial lactate measurements and fluid infusion of 30 mL/kg 4 6,208 7,099 5,632 6,752 Assessing fluid responsiveness 3 99 109 102 111 Assessing SEP-1 1 94 110 35 48 After screening of 56,563 references, 18 reports representing 20 studies met inclusion criteria and compared survival in septic patients receiving one or more of the SEP-1 interventions versus a control group. Meta-analysis was not performed because of the large heterogeneity between included studies (...) Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 73, Issue 4, Pages 363–365 Does the Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Improve Survival in Septic Adults? x

Full Text available with Trip Pro

2019 Annals of Emergency Medicine Systematic Review Snapshots

167. Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1)

Dolutegravir/rilpivirine (Juluca) for the treatment of human immunodeficiency virus type 1 (HIV-1) AWMSG SECRETARIAT ASSESSMENT REPORT Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet Reference number: 2850 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics & Toxicology Centre (AWTTC). Please direct any queries to AWTTC: All Wales Therapeutics & Toxicology Centre (AWTTC) University Hospital Llandough Penlan Road Llandough Vale of Glamorgan CF64 2XX (...) awttc@wales.nhs.uk 029 2071 6900 This report should be cited as: All Wales Therapeutics & Toxicology Centre. AWMSG Secretariat Assessment Report. Dolutegravir/rilpivirine (Juluca ® ) 50 mg/25 mg film-coated tablet. Reference number: 2850. November 2018. Dolutegravir/rilpivirine (Juluca ® ). Reference number 2850. Page 1 of 14 This assessment report will be considered for review three years from the date of the Final Appraisal Recommendation. AWMSG Secretariat Assessment Report Dolutegravir

2019 All Wales Medicines Strategy Group

168. HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low. (PubMed)

HLA-B*35: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B*57 frequency is low. To identify protective human leukocyte antigen (HLA) alleles in an HIV-infected south-east Asian population, in whom HLA-B*57 prevalence is lower than other ethnic groups, and HIV-1 CRF01_AE is the dominant circulating subtype.Cross-sectional study of Thai patients with chronic HIV infection.Five hundred and fifty-seven HIV-1 CRF01_AE-infected Thais were recruited (...) . Their HLA type and viral load were determined to statistically analyze the association of each allele in viral control. In-silico molecular dynamics was also used to evaluate the effect of HLA structure variants on epitope binding.HLA-B*35:05 was identified as the most protective allele (P=0.003, q=0.17), along with HLA-B*57:01 (P=0.044, q=0.31). Structurally, HLA-B*35:05 belonged to the HLA-B*35-PY group of HLA-B*35 alleles; however, unlike the other HLA-B*35 alleles that carry Arg (R) at residue 97

Full Text available with Trip Pro

2014 AIDS

169. Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. (PubMed)

Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. A correlation between in vivo and in vitro virus control mediated by CD8+ T-cell populations has been demonstrated by CD8 T-cell-mediated inhibition of HIV-1 and SIV replication in vitro in peripheral blood mononuclear cells (PBMCs) from infected humans and non-human primates (NHPs), respectively. Here, the breadth and specificity of T-cell responses (...) induced following vaccination with replication-defective adenovirus serotype 35 (Ad35) vectors containing a fusion protein of Gag, reverse transcriptase (RT), Integrase (Int) and Nef (Ad35-GRIN) and Env (Ad35-ENV), derived from HIV-1 subtype A isolates, was assessed in 25 individuals. The vaccine induced responses to a median of 4 epitopes per vaccinee. We correlated the CD8 responses to conserved vs. variable regions with the ability to inhibit a panel of 7 HIV-1 isolates representing multiple clades

Full Text available with Trip Pro

2014 PloS one

170. Role of Notch-1 signaling pathway in PC12 cell apoptosis induced by amyloid beta-peptide (25–35) (PubMed)

Role of Notch-1 signaling pathway in PC12 cell apoptosis induced by amyloid beta-peptide (25–35) Recent studies have demonstrated that Notch-1 expression is increased in the hippocampus of Alzheimer's disease patients. We speculate that Notch-1 signaling may be involved in PC12 cell apoptosis induced by amyloid beta-peptide (25-35) (Aβ25-35). In the present study, PC12 cells were cultured with different doses (0, 0.1, 1.0, 10 and 100 nmol/L) of N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S (...) -phenylglycine t-butyl ester, a Notch-1 signaling pathway inhibitor, for 30 minutes. Then cultured cells were induced with Aβ25-35 for 48 hours. Pretreatment of PC12 cells with high doses of N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (> 10 nmol/L) prolonged the survival of PC12 cells after Aβ25-35 induction, decreased the expression of apoptosis-related proteins caspase-3, -8, -9, increased the activity of oxidative stress-related superoxide dismutase and catalase, inhibited

Full Text available with Trip Pro

2014 Neural Regeneration Research

171. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months (PubMed)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months  There is a need for better vaccines and vaccine strategies to reduce the burden of influenza in very young children.   This phase 1, open-label study assessed the reactogenicity, safety, and immunogenicity of an inactivated trivalent influenza vaccine (TIV) containing low doses of hemagglutinin antigen (7.5 µg each strain), adjuvanted (...) with a tocopherol-based oil-in-water emulsion Adjuvant System (AS03). Influenza vaccine-naïve children aged 6-35 months were sequentially enrolled to receive TIV-AS03D (1.48 mg tocopherol) or TIV-AS03C (2.97 mg tocopherol), then a 6-month booster of conventional TIV. The primary endpoint was the incidence of fever (axillary temperature >38 °C) for 7 days post-vaccination. Immune responses were assessed by hemagglutination-inhibition (HI) assay. Forty children were sequentially enrolled into the TIV-AS03D

Full Text available with Trip Pro

2014 Human vaccines & immunotherapeutics

172. Excess mortality and life expectancy of individuals with type 1 diabetes: a rapid review

COMPLICATIONS 34 KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 3 4.7. MICRO-VASCULAR COMPLICATIONS 35 4.8. MACRO-VASCULAR COMPLICATIONS 35 4.9. NEPHROPATHY AS A PROGNOSTIC INDICATOR 35 4.10. CARDIAC AUTONOMIC NEUROPATHY 37 4.11. WELL KNOWN RISK FACTORS REQUIRING SPECIAL ATTENTION 37 4.12. SOCIO-ECONOMIC STATUS 38 4.13. SPECIFIC FEATURES OF LONG SURVIVING PATIENTS WITH T1D 38 4.14. SECULAR TRENDS 39 4.15. CONCLUSION 39 5. SYNTHESIS 41 5.1. INTRODUCTION 41 5.2 (...) , myocardial infarction). 66-68 KCE Report 314 Excess mortality and life expectancy of individuals with type 1 diabetes 35 Severe diabetic ketoacidosis (DKA) can be life-threatening and arises when there is no insulin in the body or when it is below a critical level. T1D patients rely on insulin for survival. Insulin is necessary among others for the inhibition of lipolysis. When insulin levels are critically low or when insulin is absent lipolysis will no longer be inhibited, a situation that will lead

2019 Belgian Health Care Knowledge Centre

173. Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines (PubMed)

cells from IL-35‑injected mice and negative staining in the control group. Further study revealed that IL-35 enhanced the expression of IL-10 and TGF-β which reached their highest levels at 1 and 2 weeks after injection, respectively (p<0.01). Moreover, the expression of INF-γ and IL-12 was decreased significantly at 2 weeks after the injection of IL-35-expressing plasmid (p<0.05), and the expression of IL-17 was suppressed notably at 4 weeks after the injection (p<0.05). The intravitreal injection (...) Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines In order to explore the potential effects of interleukin (IL)-35 on IL-10, transforming growth factor-β (TGF-β), interferon-γ (INF)-γ, IL-12 and IL-17, a pcDNA3.1‑IL-35 plasmid was injected into the vitreous cavity of BALB/c mice. Enzyme-linked immunosorbent assay, western blot analysis and quantitative PCR analysis were performed to confirm the successful expression

Full Text available with Trip Pro

2016 International journal of molecular medicine

174. TNFAIP1 contributes to the neurotoxicity induced by Aβ25–35 in Neuro2a cells (PubMed)

TNFAIP1 contributes to the neurotoxicity induced by Aβ25–35 in Neuro2a cells Amyloid-beta (Aβ) accumulation is a hallmark of Alzheimer's disease (AD) that can lead to neuronal dysfunction and apoptosis. Tumor necrosis factor, alpha-induced protein 1 (TNFAIP1) is an apoptotic protein that was robustly induced in the transgenic C. elegans AD brains. However, the roles of TNFAIP1 in AD have not been investigated.We found TNFAIP1 protein and mRNA levels were dramatically elevated in primary (...) mouse cortical neurons and Neuro2a (N2a) cells exposed to Aβ25-35. Knockdown and overexpression of TNFAIP1 significantly attenuated and exacerbated Aβ25-35-induced neurotoxicity in N2a cells, respectively. Further studies showed that TNFAIP1 knockdown significantly blocked Aβ25-35-induced cleaved caspase 3, whereas TNFAIP1 overexpression enhanced Aβ25-35-induced cleaved caspase 3, suggesting that TNFAIP1 plays an important role in Aβ25-35-induced neuronal apoptosis. Moreover, we observed

Full Text available with Trip Pro

2016 BMC neuroscience

175. Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001–2013) (PubMed)

Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001–2013) Canine splenic hematoma can be indistinguishable from hemangiosarcoma on clinical presentation and grossly at the time of surgery. However, hemangiosarcoma represents an aggressive malignancy and a misdiagnosis of hematoma would forgo indications for chemotherapy. This study describes a long-term follow-up of cases with a histologic diagnosis of splenic (...) of euthanasia; 1 case was histologically confirmed. Overall prognosis for splenic hematoma appears excellent, as expected, but a small proportion of cases may have an undiagnosed malignant component.

Full Text available with Trip Pro

2016 The Canadian Veterinary Journal

176. Response: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.) (PubMed)

2016 10 6 6 0 2016 10 6 6 1 ppublish 27704742 31.482 10.3803/EnM.2016.31.3.482 PMC5053064 Nat Rev Drug Discov. 2006 Jun;5(6):493-506 16732220 Diabetes. 2009 Jul;58(7):1526-31 19401428 Mol Endocrinol. 2012 Dec;26(12):1957-60 23051593 Endocrinol Metab (Seoul). 2016 Jun;31(2):328-35 27077216 (...) Response: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.) 27704742 2018 11 13 2093-596X 31 3 2016 Sep Endocrinology and metabolism (Seoul, Korea) Endocrinol Metab (Seoul) Response: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.). 482-483 10.3803/EnM.2016.31.3.482 Ku Cheol Ryong CR http://orcid.org

Full Text available with Trip Pro

2016 Endocrinology and Metabolism

177. Letter: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.) (PubMed)

10 6 6 0 2016 10 6 6 1 ppublish 27704741 PMC5053063 31.480 10.3803/EnM.2016.31.3.480 Nat Rev Drug Discov. 2006 Jun;5(6):493-506 16732220 Biochim Biophys Acta. 2015 Jun;1852(6):1114-23 25315298 Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43 9391166 Endocrinol Metab (Seoul). 2016 Jun;31(2):328-35 27077216 Cell. 2006 Dec 15;127(6):1109-22 17112576 Nature. 2006 Nov 16;444(7117):337-42 17086191 Endocrinology. 2000 Oct;141(10):3657-67 11014220 (...) Letter: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.) 27704741 2018 11 13 2093-596X 31 3 2016 09 Endocrinology and metabolism (Seoul, Korea) Endocrinol Metab (Seoul) Letter: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.). 480-481 10.3803/EnM.2016.31.3.480 Cha Ji Young JY 0000-0002-8557-6214

Full Text available with Trip Pro

2016 Endocrinology and Metabolism

178. Exposure to Melan-A/MART-126-35 tumor epitope specific CD8+T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS) (PubMed)

for failure of such therapies. Here, we show that short-term co-culture of Melan-A/MART-1 tumor antigen-expressing melanoma cells with Melan-A/MART-126-35-specific cytotoxic T lymphocytes (CTL) led to resistance against CTL-induced lysis because of impaired Melan-A/MART-126-35 epitope processing. Interestingly, deregulation of p97/VCP expression, which is an IFN-γ-independent component of the UPS and part of the ER-dependent protein degradation pathway (ERAD), was found to be essentially involved (...) Exposure to Melan-A/MART-126-35 tumor epitope specific CD8+T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS) Efficient processing of target antigens by the ubiquitin-proteasome-system (UPS) is essential for treatment of cancers by T cell therapies. However, immune escape due to altered expression of IFN-γ-inducible components of the antigen presentation machinery and consequent inefficient processing of HLA-dependent tumor epitopes can be one important reason

Full Text available with Trip Pro

2016 Scientific reports

179. RE: Long-term efficacy of microbiology-driven periodontal laser-assisted therapy, by Martelli et al., Eur J Clin Microbiol Infect Dis 2016, 35(3): 423-431 (PubMed)

. 2014 Nov;41(11):1069-79 25164559 J Clin Periodontol. 2004 Sep;31(9):749-57 15312097 Lasers Med Sci. 2014 May;29(3):887-95 23474742 J Clin Periodontol. 2007 Aug;34(8):682-90 17635246 J Clin Periodontol. 2014 Jul;41(7):681-92 24460795 J Clin Periodontol. 2010 Jun;37(6):526-33 20507376 J Periodontol. 2001 Jun;72 (6):767-73 11453239 Ann Periodontol. 1999 Dec;4(1):1-6 10863370 Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):423-31 26740323 J Clin Periodontol. 2002 May;29 Suppl 2:6-16 12010523 J (...) RE: Long-term efficacy of microbiology-driven periodontal laser-assisted therapy, by Martelli et al., Eur J Clin Microbiol Infect Dis 2016, 35(3): 423-431 27738855 2017 02 15 2018 11 13 1435-4373 36 2 2017 Feb European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology Eur. J. Clin. Microbiol. Infect. Dis. RE: Long-term efficacy of microbiology-driven periodontal laser-assisted therapy, by Martelli et al., Eur J Clin

Full Text available with Trip Pro

2016 European Journal of Clinical Microbiology & Infectious Diseases

180. Corrigendum to “Esophageal remnant cancer 35 years after acidic caustic injury: A case report” [Int. J. Surg. Case Rep. 25 (2016) 215–217] (PubMed)

Corrigendum to “Esophageal remnant cancer 35 years after acidic caustic injury: A case report” [Int. J. Surg. Case Rep. 25 (2016) 215–217] 27810604 2017 08 16 2210-2612 29 2016 International journal of surgery case reports Int J Surg Case Rep Corrigendum to "Esophageal remnant cancer 35 years after acidic caustic injury: A case report" [Int. J. Surg. Case Rep. 25 (2016) 215-217]. 16 S2210-2612(16)30431-X 10.1016/j.ijscr.2016.10.034 Ntanasis-Stathopoulos Ioannis I Department of Foregut (...) D Department of Foregut Surgery, 1st Propaedeutic Surgical Clinic, "Hippokration" General Hospital of Athens, National and Kapodistrian University of Athens, 114 Vas. Sofias Av., 11527 Athens, Greece. eng Published Erratum 2016 10 27 Netherlands Int J Surg Case Rep 101529872 2210-2612 2016 11 5 6 0 2016 11 5 6 1 2016 11 5 6 0 ppublish 27810604 S2210-2612(16)30431-X 10.1016/j.ijscr.2016.10.034 PMC5094154

Full Text available with Trip Pro

2016 International journal of surgery case reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>